A disproportionality analysis of real-world events from the FDA Adverse Event Reporting System (FAERS) for Atezolizumab
Sign Up to like & getrecommendations! Published in 2025 at "BMC Pharmacology & Toxicology"
DOI: 10.1186/s40360-025-00879-2
Abstract: An increasing number of clinical studies have highlighted the use of atezolizumab in tumor immunotherapy. However, There is still a lack of comprehensive research on its associated adverse events (AEs). To improve our understanding of… read more here.
Keywords: lower limit; ror lower; limit prr; reporting ... See more keywords